Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study.
OBJECTIVE
To investigate the response to sumatriptan in migraineurs with unilateral cranial autonomic symptoms such as lacrimation, eye redness, eyelid edema, nasal congestion, and rhinorrhea.


BACKGROUND
Given the potential large-scale recruitment of peripheral neurovascular 5-HT1B/1D receptors consequent to the activation of the trigeminal autonomic reflex in such patients, the presence of unilateral cranial autonomic symptoms may predict a positive response to sumatriptan.


METHODS
Seventy-two consecutive migraineurs with unilateral cranial autonomic symptoms were given sumatriptan 50-mg tablets to treat 1 migraine attack and were asked to record their clinical response to the drug at different time points. End points were pain-relief and pain-free response at 1 and 2 hours.


RESULTS
Pain relief was reported by 47 patients (65.3%) at 1 hour and by 59 (81.9%) at 2 hours. Pain-free response was reported by 22 patients (30.6%) at 1 hour and by 44 (61.1%) at 2 hours. Responsiveness to sumatriptan did not correlate with the type or number of unilateral cranial autonomic symptoms, demographic characteristics, prophylactic treatments, use of contraceptives, or concomitant tension-type headache.


CONCLUSIONS
Migraineurs with unilateral cranial autonomic symptoms seem to respond to sumatriptan better than other migraineurs. The presence of unilateral cranial autonomic symptoms may predict a positive response to the triptans.
Barbanti
Piero
P
Department of Neurosciences, University La Sapienza, Viale dell'Università 30, 00185 Rome, Italy.
Fabbrini
Giovanni
G
Vanacore
Nicola
N
Pesare
Marina
M
Buzzi
Maria Gabriella
MG
D000328:Adult; D001341:Autonomic Nervous System / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use*; D016896:Treatment Outcome; D014276:Trigeminal Nerve / Q000187:drug effects / Q000503:physiopathology
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan